CTIS2023-507418-28-00
Recruiting
Phase 1
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial - BO41932
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Solid tumors
- Sponsor
- F. Hoffmann-La Roche AG
- Enrollment
- 825
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically or cytologically confirmed diagnosis of advanced and unresectable or metastatic solid malignancy, Measurable disease as defined by Response Evaluation Criteria in Solid Tumors, Version 1\.1 (RECIST v1\.1\), Response Assessment in Neuro\-Oncology (RANO) criteria, or International Neuroblastoma Response Criteria (INRC), Performance status as follows: Participants aged \= 18 years: Eastern Cooperative Oncology Group (ECOG) Performance Status 0\-2; Participants aged 16 to \< 18 years: Karnofsky score \= 50%; Participants aged \< 16 years: Lansky score \= 50%, For participants aged \= 18 and \<18 years: adequate hematologic and end\-organ function, Disease progression on prior treatment, or previously untreated disease with no available acceptable treatment, Adequate recovery from most recent systemic or local treatment for cancer
Exclusion Criteria
- •Current participation or enrollment in another therapeutic clinical trial, Any anticancer treatment within 2 weeks prior to start of study treatment (Please refer to the cohort\-specific eligibility criteria for requirements on enrollment, if applicable), Whole brain radiotherapy within 14 days prior to start of study treatment, Stereotactic radiosurgery within 7 days prior to start of study treatment, Pregnant or breastfeeding, or intending to become pregnant during the study, History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study or confounds the ability to interpret data from the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Suspended
Phase 2
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyRET fusion-positive solid tumors other than NSCLCJPRN-jRCT2031210670David Chen770
Active, not recruiting
Phase 1
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (Tapistry) Phase II Platform TrialSolid tumorsMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-001847-16-PTF. Hoffmann-La Roche Ltd4
Active, not recruiting
Phase 1
To Study Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trialocally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are TMB-high as identified by a validated NGS assayMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-001847-16-ITF. HOFFMANN - LA ROCHE LTD.650
Active, not recruiting
Phase 1
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (Tapistry) Phase II Platform Trialocally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are TMB-high as identified by a validated NGS assayMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-001847-16-DKF. Hoffmann-La Roche Ltd920
Active, not recruiting
Phase 1
To Study Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trialocally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are TMB-high as identified by a validated NGS assayMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-001847-16-NLF. Hoffmann-La Roche Ltd600